It's most likely that established vaccine developers, such as London-based GlaxoSmithKline and Sanofi Aventis of Paris, would pump out stockpiles of any pandemic flu vaccine, but it is the small biotechs that literally rise and fall with the world's pandemic concerns. Note Birmingham, Alabama–based BioCryst, developer of the clinical stage neuraminidase inhibitor peramivir, for influenza. The firm received a 90% stock boost to $3.29 on April 27, after the H1N1 influenza (swine flu) grabbed headlines. And in London, Lipoxen on April 30 announced positive preclinical results for the delivery of an enhanced influenza vaccine, adding that the technology should also work against the new swine flu strain. Investors boosted Lipoxen's share price from £6.62 ($10.11) to £21.75 ($33.23). Also consider Rockville, Maryland–based vaccine developer Novavax. The company's stock slowly lost ground this year, dropping from $2 per share to around 85 cents in mid-April. But when swine flu became the topic of conversation, Novavax's shares jumped more than 200% to $2.55 over two sessions. Similarly, in 2005, when the flu was avian rather than swine, Novavax's shares traded at less than a dollar for most of that summer. However, in the fall, when the company's avian flu vaccine, manufactured using their virus-like particle technology, performed well in animal models, Novavax's stock jumped to close as high as $5.53.